Swine Mycoplasma Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510240736

Publication Date:

October 17, 2024

Pages:

119

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Agriculture [2]

Industry & Manufacturing [3]

Description:

Swine mycoplasma vaccine is a type of vaccine that is designed to prevent mycoplasma infections in pigs. Mycoplasmas are bacteria that can cause a variety of respiratory and reproductive diseases in pigs, such as enzootic pneumonia, arthritis, and urinary tract infections.
The global market for Swine Mycoplasma Vaccine was estimated to be worth US$ 647 million in 2023 and is forecast to a readjusted size of US$ 1117.4 million by 2030 with a CAGR of 7.8% during the forecast period 2024-2030
North American market for Swine Mycoplasma Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Swine Mycoplasma Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Swine Mycoplasma Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Swine Mycoplasma Vaccine include Zoetis, Boehringer Ingelheim, Jinhe Biotechnology, Merck, HIPRA, Ceva Sant茅 Animale, Harbin Pharmaceutical Group, Pulike Biotech and Qilu Animal Health Products, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Swine Mycoplasma Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Swine Mycoplasma Vaccine by region & country, by Type, and by Application.
The Swine Mycoplasma Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Swine Mycoplasma Vaccine.
Market Segmentation
By Company
Zoetis
Boehringer Ingelheim
Jinhe Biotechnology
Merck
HIPRA
Ceva Sant茅 Animale
Harbin Pharmaceutical Group
Pulike Biotech
Qilu Animal Health Products
Wuhan Keqian Biology
Guangdong Winsun Bio-Pharmaceutical
Segment by Type:
Inactivated Vaccines
Live Vaccines
Segment by Application
Piglets
Adult Pigs
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Swine Mycoplasma Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Swine Mycoplasma Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Swine Mycoplasma Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Swine Mycoplasma Vaccine Product Introduction
1.2 Global Swine Mycoplasma Vaccine Market Size Forecast
1.2.1 Global Swine Mycoplasma Vaccine Sales Value (2019-2030)
1.2.2 Global Swine Mycoplasma Vaccine Sales Volume (2019-2030)
1.2.3 Global Swine Mycoplasma Vaccine Sales Price (2019-2030)
1.3 Swine Mycoplasma Vaccine Market Trends & Drivers
1.3.1 Swine Mycoplasma Vaccine Industry Trends
1.3.2 Swine Mycoplasma Vaccine Market Drivers & Opportunity
1.3.3 Swine Mycoplasma Vaccine Market Challenges
1.3.4 Swine Mycoplasma Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Swine Mycoplasma Vaccine Players Revenue Ranking (2023)
2.2 Global Swine Mycoplasma Vaccine Revenue by Company (2019-2024)
2.3 Global Swine Mycoplasma Vaccine Players Sales Volume Ranking (2023)
2.4 Global Swine Mycoplasma Vaccine Sales Volume by Company Players (2019-2024)
2.5 Global Swine Mycoplasma Vaccine Average Price by Company (2019-2024)
2.6 Key Manufacturers Swine Mycoplasma Vaccine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Swine Mycoplasma Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Swine Mycoplasma Vaccine
2.9 Swine Mycoplasma Vaccine Market Competitive Analysis
2.9.1 Swine Mycoplasma Vaccine Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Swine Mycoplasma Vaccine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Swine Mycoplasma Vaccine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Inactivated Vaccines
3.1.2 Live Vaccines
3.2 Global Swine Mycoplasma Vaccine Sales Value by Type
3.2.1 Global Swine Mycoplasma Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Swine Mycoplasma Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Swine Mycoplasma Vaccine Sales Value, by Type (%) (2019-2030)
3.3 Global Swine Mycoplasma Vaccine Sales Volume by Type
3.3.1 Global Swine Mycoplasma Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Swine Mycoplasma Vaccine Sales Volume, by Type (2019-2030)
3.3.3 Global Swine Mycoplasma Vaccine Sales Volume, by Type (%) (2019-2030)
3.4 Global Swine Mycoplasma Vaccine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Piglets
4.1.2 Adult Pigs
4.2 Global Swine Mycoplasma Vaccine Sales Value by Application
4.2.1 Global Swine Mycoplasma Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Swine Mycoplasma Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Swine Mycoplasma Vaccine Sales Value, by Application (%) (2019-2030)
4.3 Global Swine Mycoplasma Vaccine Sales Volume by Application
4.3.1 Global Swine Mycoplasma Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Swine Mycoplasma Vaccine Sales Volume, by Application (2019-2030)
4.3.3 Global Swine Mycoplasma Vaccine Sales Volume, by Application (%) (2019-2030)
4.4 Global Swine Mycoplasma Vaccine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Swine Mycoplasma Vaccine Sales Value by Region
5.1.1 Global Swine Mycoplasma Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Swine Mycoplasma Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Swine Mycoplasma Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Swine Mycoplasma Vaccine Sales Value by Region (%), (2019-2030)
5.2 Global Swine Mycoplasma Vaccine Sales Volume by Region
5.2.1 Global Swine Mycoplasma Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Swine Mycoplasma Vaccine Sales Volume by Region (2019-2024)
5.2.3 Global Swine Mycoplasma Vaccine Sales Volume by Region (2025-2030)
5.2.4 Global Swine Mycoplasma Vaccine Sales Volume by Region (%), (2019-2030)
5.3 Global Swine Mycoplasma Vaccine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Swine Mycoplasma Vaccine Sales Value, 2019-2030
5.4.2 North America Swine Mycoplasma Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Swine Mycoplasma Vaccine Sales Value, 2019-2030
5.5.2 Europe Swine Mycoplasma Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Swine Mycoplasma Vaccine Sales Value, 2019-2030
5.6.2 Asia Pacific Swine Mycoplasma Vaccine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Swine Mycoplasma Vaccine Sales Value, 2019-2030
5.7.2 South America Swine Mycoplasma Vaccine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Swine Mycoplasma Vaccine Sales Value, 2019-2030
5.8.2 Middle East & Africa Swine Mycoplasma Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Swine Mycoplasma Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Swine Mycoplasma Vaccine Sales Value
6.2.1 Key Countries/Regions Swine Mycoplasma Vaccine Sales Value, 2019-2030
6.2.2 Key Countries/Regions Swine Mycoplasma Vaccine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Swine Mycoplasma Vaccine Sales Value, 2019-2030
6.3.2 United States Swine Mycoplasma Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Swine Mycoplasma Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Swine Mycoplasma Vaccine Sales Value, 2019-2030
6.4.2 Europe Swine Mycoplasma Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Swine Mycoplasma Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Swine Mycoplasma Vaccine Sales Value, 2019-2030
6.5.2 China Swine Mycoplasma Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Swine Mycoplasma Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Swine Mycoplasma Vaccine Sales Value, 2019-2030
6.6.2 Japan Swine Mycoplasma Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Swine Mycoplasma Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Swine Mycoplasma Vaccine Sales Value, 2019-2030
6.7.2 South Korea Swine Mycoplasma Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Swine Mycoplasma Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Swine Mycoplasma Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Swine Mycoplasma Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Swine Mycoplasma Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Swine Mycoplasma Vaccine Sales Value, 2019-2030
6.9.2 India Swine Mycoplasma Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Swine Mycoplasma Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Zoetis
7.1.1 Zoetis Company Information
7.1.2 Zoetis Introduction and Business Overview
7.1.3 Zoetis Swine Mycoplasma Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Zoetis Swine Mycoplasma Vaccine Product Offerings
7.1.5 Zoetis Recent Development
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Information
7.2.2 Boehringer Ingelheim Introduction and Business Overview
7.2.3 Boehringer Ingelheim Swine Mycoplasma Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Boehringer Ingelheim Swine Mycoplasma Vaccine Product Offerings
7.2.5 Boehringer Ingelheim Recent Development
7.3 Jinhe Biotechnology
7.3.1 Jinhe Biotechnology Company Information
7.3.2 Jinhe Biotechnology Introduction and Business Overview
7.3.3 Jinhe Biotechnology Swine Mycoplasma Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Jinhe Biotechnology Swine Mycoplasma Vaccine Product Offerings
7.3.5 Jinhe Biotechnology Recent Development
7.4 Merck
7.4.1 Merck Company Information
7.4.2 Merck Introduction and Business Overview
7.4.3 Merck Swine Mycoplasma Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Merck Swine Mycoplasma Vaccine Product Offerings
7.4.5 Merck Recent Development
7.5 HIPRA
7.5.1 HIPRA Company Information
7.5.2 HIPRA Introduction and Business Overview
7.5.3 HIPRA Swine Mycoplasma Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 HIPRA Swine Mycoplasma Vaccine Product Offerings
7.5.5 HIPRA Recent Development
7.6 Ceva Sant茅 Animale
7.6.1 Ceva Sant茅 Animale Company Information
7.6.2 Ceva Sant茅 Animale Introduction and Business Overview
7.6.3 Ceva Sant茅 Animale Swine Mycoplasma Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Ceva Sant茅 Animale Swine Mycoplasma Vaccine Product Offerings
7.6.5 Ceva Sant茅 Animale Recent Development
7.7 Harbin Pharmaceutical Group
7.7.1 Harbin Pharmaceutical Group Company Information
7.7.2 Harbin Pharmaceutical Group Introduction and Business Overview
7.7.3 Harbin Pharmaceutical Group Swine Mycoplasma Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Harbin Pharmaceutical Group Swine Mycoplasma Vaccine Product Offerings
7.7.5 Harbin Pharmaceutical Group Recent Development
7.8 Pulike Biotech
7.8.1 Pulike Biotech Company Information
7.8.2 Pulike Biotech Introduction and Business Overview
7.8.3 Pulike Biotech Swine Mycoplasma Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Pulike Biotech Swine Mycoplasma Vaccine Product Offerings
7.8.5 Pulike Biotech Recent Development
7.9 Qilu Animal Health Products
7.9.1 Qilu Animal Health Products Company Information
7.9.2 Qilu Animal Health Products Introduction and Business Overview
7.9.3 Qilu Animal Health Products Swine Mycoplasma Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Qilu Animal Health Products Swine Mycoplasma Vaccine Product Offerings
7.9.5 Qilu Animal Health Products Recent Development
7.10 Wuhan Keqian Biology
7.10.1 Wuhan Keqian Biology Company Information
7.10.2 Wuhan Keqian Biology Introduction and Business Overview
7.10.3 Wuhan Keqian Biology Swine Mycoplasma Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Wuhan Keqian Biology Swine Mycoplasma Vaccine Product Offerings
7.10.5 Wuhan Keqian Biology Recent Development
7.11 Guangdong Winsun Bio-Pharmaceutical
7.11.1 Guangdong Winsun Bio-Pharmaceutical Company Information
7.11.2 Guangdong Winsun Bio-Pharmaceutical Introduction and Business Overview
7.11.3 Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Vaccine Product Offerings
7.11.5 Guangdong Winsun Bio-Pharmaceutical Recent Development
8 Industry Chain Analysis
8.1 Swine Mycoplasma Vaccine Industrial Chain
8.2 Swine Mycoplasma Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Swine Mycoplasma Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Swine Mycoplasma Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Zoetis
Boehringer Ingelheim
Jinhe Biotechnology
Merck
HIPRA
Ceva Sant茅 Animale
Harbin Pharmaceutical Group
Pulike Biotech
Qilu Animal Health Products
Wuhan Keqian Biology
Guangdong Winsun Bio-Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂